Is Global Health overvalued or undervalued?

As of 10 November 2025, the valuation grade for Global Health has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 52.88, an EV to EBITDA of 32.75, and a Price to Book Value of 9.36. In comparison to its peers, Max Healthcare has a significantly higher PE ratio of 88.71, while Apollo Hospitals, which is rated attractive, has a PE ratio of 64.78. Despite a recent decline in stock price, with a 1-month return of -12.53% compared to a Sensex return of 1.25%, Global Health's performance over the year remains positive at 9.44%. However, the elevated valuation ratios suggest that the stock may not offer sufficient upside potential relative to its current price.